• Cefpodoxime proxetil in an acute bronchitis treatment of the bacterial etiology among children
To content

Cefpodoxime proxetil in an acute bronchitis treatment of the bacterial etiology among children

SOVREMENNAYA PEDIATRIYA.2014.4(60):100105; doi 10.15574/SP.2014.60.100 

Cefpodoxime proxetil in an acute bronchitis treatment of the bacterial etiology among children

Marushko Y. V. 
The National Medical University named after A.A. Bogomolets, Kiev, Ukraine

Purpose: studying the effectiveness, the security profiles and commitment to the therapy using the cefpodoxime proxetil in an acute bronchitis treatment of the bacterial etiology among children in age from 247 years.

Patients and methods: there were 32 children under the observation. 18 (56.3%) patients had a clinical bronchitis features simultaneously with the ENT 4diseases or during a day after their occurrence ; the others 14 (43.7%) patients had a febrile fever and a clinical bronchitis features on a 3–5 day of ARVI flowing. The bronchitis treatment and the related diseases performed in accordance with the protocols. Cefpodoxime proxetil (Cefrodox) appointed in the suspension form twice per day during 7 days term.The dynamics rate of the symptoms was performed before the treatment assignment, on 3 and 8 days with an antibiotic therapy. The intensity of intoxication syndrome was studied, the cough frequency and its productivity, the wheezes quantity during the lungs auscultation.

Results: on the third day of the cefpodoxime proxetil treatment therapy all the patients had an intoxication syndrome and fever disappearing; after the seven days treatment all the patients had the better laboratory blood index, more than 1/2 had any clinical bronchitis displays; on the tenth day the clinical disease displays were not observed. It was set a high adherence to treatment, an absence of the allergic reactions.

Conclusion: cefpodoxime proxetil drug is an effective in an acute bronchitis therapy, and is associated with the age compliance degree and the low frequency of the side effects incidence.

Key words: the cefpodoxime proxetil, children, an acute bacterial bronchitis.

REFERENCES 
1. Бережной ВВ, Козачук ВГ, Орлюк ИБ, Кирнос АИ. 2011. Опыт использования препарата цефодокс в комплексной терапии гнойных синуситов у детей. Здоровье Украины. Педиатрия. Тематич номер: 52—53.

2. Тяжка ОВ та ін. 2011. Застосування цефподоксиму проксетилу в дитячій практиці. Здоровье Украины. Педиатрия. Тематич номер: 41—42.

3. Катилов АВ, Дмитриев ДВ. 2012. Бронхиты у детей: современные представления. Дитячий лікар. 3—4: 18—25.

4. Боярская ЛН, Котлова ЮВ, Крыгина АН и др. 2009. Микробиологическая безопасность цефподоксима проксетила (Цефодокса) при лечении детей с острыми респираторными заболеваниями. Совр педиатрия. 2: 72—75.

5. Овчаренко ЛС, Ткаченко ВЮ. 2013. Эффективная антибиотикотерапия рекуррентных бактериальных бронхитов у детей с гипертрофией лимфоглоточного кольца. Нов медицины и фармации. 15.

6. Протокол лікування дітей з гострими бронхітами. Додаток № 2 до наказу МОЗ України № 18 «Про затвердження Протоколів надання медичної допомоги дітям за спеціальністю «Дитяча пульмонологія» від 13.01.2005 р. К. 2005: 58.

7. Волосовец АП и др. 2011. Результаты многоцентрового исследования Цеф-Просто (цефподоксима проксетил в стартовой терапии внебольничной пневмонии у детей) в Украине. Здоровье Ребенка. 2(29).

8. Wollner A et al. 2011. Acceptability, compliance and schedule of administration of oral antibiotics in outpatient children. Arch Pediatr.

9. http://emedicine.medscape.com/article/1001332 — overview-aw2aab6b2b3aa.

10. Hasan et al. 2014. Incidence and etiology of acute lower respiratory tract infections in hospitalized children younger than 5 years in rural Thailand. Pediatr Infect Dis J. 33(2): 45—52. http://dx.doi.org/10.1097/INF.0000000000000062; PMid:24030346

11. Hsueh PR et al. 2004. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. J Formos Med Assoc. 103(9): 664—670.